FL-MITSUBISHI-POWER
23.6.2022 15:07:13 CEST | Business Wire | Press release
Renewable energy developer Ion Renewables, Ltd. (ION Renewables) has signed an exclusivity agreement with Mitsubishi Power Americas, Inc. (Mitsubishi Power) for four battery energy storage system (BESS) projects using Mitsubishi Power’s Emerald storage solutions totaling 185.5 megawatt (MW) / 371 megawatt-hours (MWh) in Ireland. These projects will provide Secure, Sustainable Electricity System (DS3) energy storage and system services including fast frequency and capacity response to Ireland’s National Grid, enabling the addition of more renewable energy. All four projects will be located at brownfield sites with existing electrical interconnects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622006036/en/
In addition to providing frequency response to the National Grid, the BESS projects will support three major energy initiative programs for Ireland and the European Union:
- Ireland’s Climate Action Plan to reach net-zero greenhouse gas emissions no later than 2050
- EirGrid Group’s DS3 program that addresses the challenges of integrating world-leading levels of renewable generation into the grid and targets having 70% of Ireland’s electricity come from renewables by 2030
- REPowerEU’s draft directive, which seeks to eliminate imported gas by 2030 and diversify energy sources
“We are delighted to be working with the Mitsubishi Power team to deliver these important projects,” said John Ward, Director, ION Renewables. “These installations represent a viable and economical solution to balance the network, strongly aligning with the principles of the REPowerEU draft directive. These projects demonstrate that effective solutions for storing energy can be achieved by utilizing renewable power that would otherwise be curtailed.”
Scheduled to come online in 2024, the four BESS projects will be Mitsubishi Power’s first in Europe, bringing the total global deployment of its Emerald storage solutions to more than 2 gigawatt-hours (GWh).
Mitsubishi Power’s Emerald storage solutions for Ion Renewables include project engineering, equipment supply, and a 10-year long-term service agreement.
According to Tom Cornell, Senior Vice President, Energy Storage Solutions, Mitsubishi Power Americas, these projects emphasize the importance of BESS adoption as a viable solution with more countries striving to meet their climate action goals. “Bringing our Emerald storage solutions to Ireland and working with Ion Renewables is an exciting moment for us. The continued adoption of battery storage technologies outside of the United States and the recognition of the important role they play in enabling renewable energy generation to reach net-zero cannot be overstated. Mitsubishi Power’s Emerald storage solutions will help Ireland reach its goal of 70% generation from renewable sources while ensuring the stability of the grid with a secure power system.”
Read more about some of Mitsubishi Power’s BESS projects:
- Innergex Orders Mitsubishi Power Emerald Storage Solution to Bring 425 Megawatt-hours of Battery Storage to Chile
- San Diego Gas & Electric Orders Mitsubishi Power Emerald Storage Solution to Add Capacity for High Energy Demand
- Mitsubishi Power and Powin Partner to Enhance California’s Grid Reliability with Two Battery Energy Storage Projects
- MHPS Will Supply Battery Energy Storage Systems to Help Balance the California Grid
- Key Capture Energy, Mitsubishi Hitachi Power Systems, and Powin Energy Partner to Add 200 MW of Battery Storage to the Texas Grid
About Mitsubishi Power Americas, Inc.
Mitsubishi Power Americas, Inc. (Mitsubishi Power) headquartered in Lake Mary, Florida, employs more than 2,300 power generation, energy storage, and digital solutions experts and professionals. Our employees are focused on empowering customers to affordably and reliably combat climate change while also advancing human prosperity throughout North, Central, and South America. Mitsubishi Power’s power generation solutions include gas, steam, and aero-derivative turbines; power trains and power islands; geothermal systems; PV solar project development; environmental controls; and services. Energy storage solutions include green hydrogen, battery energy storage systems, and services. Mitsubishi Power also offers intelligent solutions that use artificial intelligence to enable autonomous operation of power plants. Mitsubishi Power is a power solutions brand of Mitsubishi Heavy Industries, Ltd. (MHI). Headquartered in Tokyo, Japan, MHI is one of the world’s leading heavy machinery manufacturers with engineering and manufacturing businesses spanning energy, infrastructure, transport, aerospace, and defense. For more information, visit the Mitsubishi Power Americas website and follow us on LinkedIn .
About Ion Renewables, Ltd.
Ion Renewables, Ltd. (ION Renewables) was formed by top experts in the energy storage industry with the goal of deploying energy storage to provide grid balancing and renewables integration. We are developing and advising on projects in Ireland and worldwide through our network. In this current batch of projects in Ireland, ION Renewables is developing ESS facilities at large industrial load centres, providing rapid deployment and low environmental footprint on existing brownfield sites. These projects will assist in balancing the network by providing additional functionality to the grid to enable the further deployment of renewables and ultimately reduce Ireland's dependency on imported fossil fuels. For more information, visit the ION Renewables website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622006036/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
